ClinicalTrials.gg
CompletedNCT04536688Updated Dec 15, 2021

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

A Phase 1 interventional study of RGLS4326 in Polycystic Kidney Disease, Autosomal Dominant, sponsored by Regulus Therapeutics Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-12-15.

Sponsored by Regulus Therapeutics Inc. (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Enrollment
51st of 63
19 · median 48
Started
2020
with 3 others
Phase 1
10 of 85
2 open now
Registered
57th of 85
by date
Lead sponsor
3 of 85
Regulus Therapeutics Inc.

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 51st largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2020, is one of 10 in phase 1, and was the 57th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

Primary Objective

  • To assess the dose response relationship between RGLS4326 and ADPKD biomarkers

Secondary Objectives

  • To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine
  • To assess the safety and tolerability of RGLS4326
Read the detailed description

This is a Phase 1b, open-label, adaptive design dose-ranging study to evaluate ADPKD biomarkers, PK, safety, tolerability, and pharmacodynamics (PD) of RGLS4326 administered via SC injection to patients with ADPKD. The goal is to assess the dose response relationship between RGLS4326 and ADPKD biomarkers. The study will consist of three sequential cohorts with approximately 18 to 27 subjects total.

03

Conditions studied

  • Polycystic Kidney Disease, Autosomal Dominant
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ADPKD patients 18 to 70 years old
  • Class 1C, 1D, or 1E Mayo Imaging Classification of ADPKD (based upon prior MRI or CT Scan or MRI obtained during screening)
  • Estimated at Screening between 30 to 90 mL/min/1.73 m\^2 calculated by the investigator using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI)
  • (BMI) between 18 and 35 kg/m\^2
  • If the patient has hypertension, the antihypertensive regimen must be stable for at least 28 days prior to randomization and the blood pressure adequately controlled prior to randomization
  • Female patients of must not be lactating and must have no plans to become pregnant during the course of the study through 28 days after the last dose of study drug. Female patients of childbearing potential who are heterosexual must agree to use one of the following methods of considered to be highly effective (i.e., results in \<1% failure rate when used consistently and correctly) from screening through 28 days after the last dose of study drug:

    • Intrauterine device (IUD) or intrauterine system (IUS) in place for at least 3 months prior to first dose
    • Partner has had a vasectomy. Vasectomy in the partner is only considered to be highly effective provided the partner is the sole sexual partner of the female patient of childbearing potential and the vasectomized partner has had a medical assessment of the surgical success.
    • Stable hormonal contraception associated with inhibition of ovulation (with approved oral, transdermal, or depot regimen) for at least 3 months prior to first dose
    • Bilateral tubal occlusion
  • Female patient of non-childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to the first dose of study drug:

    • Hysterectomy
    • Bilateral oophorectomy
    • Bilateral tubal occlusion
    • Bilateral salpingectomy or be with no periods for at least 1 year prior to the first dose of study drug.
  • Male patients must agree to use a condom during heterosexual intercourse and to not have unprotected sexual intercourse with a female who is pregnant or breastfeeding from screening through 28 days after the last dose of study drug; and must agree to refrain from sperm donation for at least 90 days after the last dose of study drug
  • Screening hematology and clinical chemistries must meet the following criteria:

    • >150 x 10\^9/L
    • Total white blood cell (WBC) count >3.0 x 10\^9/L and >1.5 x 10\^9/L
    • >12 g/dL for females and >13.5 g/dL for males
    • Total and direct \<1.5x (ULN), unless elevated bilirubin is associated with a known benign condition (e.g., Gilbert's syndrome)
    • (ALT) \<1.5x ULN
    • Aspartate aminotransferase (AST) \<1.5x ULN
    • Alkaline phosphatase (ALP) \<1.5x ULN
    • Gamma-glutamyl transferase (GGT) \<2x ULN Note: At the discretion of the Investigator, screening laboratory testing may be repeated once to confirm out of range (exclusionary) results.
  • Able to understand all study procedures in the form (ICF) and willing to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  • Administration of tolvaptan in the 28 days before randomization
  • Participation in another interventional study within 28 days or 5 half-lives, whichever is longer, before randomization (e.g., bardoxolone, lixivaptan, tesevatinib, venglustat)
  • A history of drug and/or alcohol abuse within the past year
  • Active infection of the urinary tract (e.g., kidney, bladder, etc.)
  • Known , , or (HIV)
  • Only one kidney or kidney transplant recipient.
  • Patient has concurrent medical condition (e.g., significant infection, other kidney disease, neurologic condition such as seizures, etc.) or social situation that may either present a safety risk or noncompliance with the study procedures
  • History of active within 5 years of randomization, except adequately treated basal cell or squamous cell carcinoma of the skin
  • History of a reaction to an oligonucleotide compound
  • Significant blood loss or blood donation within the 28 days prior to randomization or plasma donation within 7 days prior to randomization
  • A tattoo or scarring on the abdomen or any other condition large enough to interfere with the ability to assess injection site reactions
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    RGLS4326 1 mg/kg Q2W

    Eligible participants will receive subcutaneous injection of 1 mg/kg of RGLS4326 every other week for 4 doses

    Drug: RGLS4326

  • Experimental
    RGLS4326 0.3 mg/kg Q2W

    Eligible participants will receive subcutaneous injection of 0.3 mg/kg of RGLS4326 every other week for 4 doses

    Drug: RGLS4326

  • Experimental
    RGLS4326 0.1 or 0.5 mg/kg Q2W

    Eligible participants will receive subcutaneous injection of 0.1 or 0.5 mg/kg of RGLS4326 every other week for 4 doses

    Drug: RGLS4326

Interventions

  • DrugRGLS4326

    Solution for subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Changes in primary biomarker levels from baseline

    Changes in polycystin-1 (PC-1) and polycystin-2 (PC-2) protein levels in urinary exosomes from baseline to Day 44

    Time frame: Baseline to Day 44

Secondary outcomes

  1. Changes in secondary biomarker levels from baseline

    Changes in neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) in urine from baseline to Day 44

    Time frame: Baseline to Day 44

  2. Pharmacokinetics (Cmax)

    Maximum concentration (Cmax) of RGLS4326 in plasma following RGLS4326 treatment

    Time frame: Baseline to Day 44

  3. Pharmacokinetics (Tmax)

    Time to maximum concentration (Tmax) of RGLS4326 in plasma following RGLS4326 treatment

    Time frame: Baseline to Day 71

  4. Pharmacokinetics (AUC)

    Area under the curve (AUC) of RGLS4326 in plasma following RGLS4326 treatment

    Time frame: Baseline to Day 71

  5. Number of participants with anti-drug antibodies (ADAs)

    Incidence of ADAs following RGLS4326 treatment from baseline to Day 71

    Time frame: Baseline to Day 71

  6. Titre of anti-drug antibodies (ADAs) in patients with ADAs

    Titre of ADAs following RGLS4326 treatment from baseline to Day 71

    Time frame: Baseline to Day 71

  7. Safety profile

    Incidence of AEs, lab abnormalities, and ECG abnormalities following RGLS4326 treatment

    Time frame: Baseline to Day 71

07

Study locations

12 sites
  • Balboa Nephrology Medical Group
    La Mesa, California 91942, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Yale Nephrology Clinical Research
    New Haven, Connecticut 06510, United States
  • Accel Research Sites- Mid-Florida Kidney and Hypertension Care
    Altamonte Springs, Florida 32701, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • St. Clair Nephrology Research
    Roseville, Michigan 48066, United States
  • Mayo Clinic
    Rochester, Minnesota 55904, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
  • Swedish Polycystic Kidney Disease Center
    Seattle, Washington 98104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Nov 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2020
First posted
Sep 3, 2020
StartActual
Oct 13, 2020
Primary completionActual
Nov 12, 2021
CompletionActual
Nov 12, 2021
Last update
Dec 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04536688
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Oct 13, 2020
Primary completion
Nov 12, 2021
Completion
Nov 12, 2021
Last update
Dec 15, 2021

Study contacts

Karl Cremer, PharmD
study director · Regulus Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion